Satellos Bioscience (NASDAQ:MSLE) Issues Quarterly Earnings Results

Satellos Bioscience (NASDAQ:MSLE) released its quarterly earnings results on Friday. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.11), Zacks reports.

Satellos Bioscience Trading Down 10.7%

NASDAQ:MSLE opened at $6.19 on Friday. Satellos Bioscience has a twelve month low of $4.53 and a twelve month high of $13.39. The company has a market cap of $95.70 million, a price-to-earnings ratio of -5.16 and a beta of 1.10.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on MSLE shares. Cantor Fitzgerald started coverage on shares of Satellos Bioscience in a research report on Wednesday, March 11th. They issued an “overweight” rating on the stock. Zacks Research raised shares of Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Weiss Ratings assumed coverage on Satellos Bioscience in a report on Wednesday, February 11th. They set a “sell (d-)” rating for the company. Finally, Wall Street Zen downgraded Satellos Bioscience to a “strong sell” rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold”.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.